[1] Alberts C J, Clifford G M, Georges D, et al. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review[J]. Lancet Gastroenterol Hepatol,2022 ,7(8):724-735. [2] He C, Liu P, Liu X, et al. Changing etiological spectrum of cirrhosis in China: a systematic review and meta-analysis[J/OL]. BMC Gastroenterol,2026. pubmed.ncbi.nlm.nih.gov/422864541. [3] Yan R, Sun M, Yang H, et al. 2024 latest report on hepatitis B virus epidemiology in China: current status, changing trajectory, and challenges[J]. Hepatobiliary Surg Nutr,2025,14(1):66-77. [4] Shan S, Zhao X, Jia J. Comprehensive approach to controlling chronic hepatitis B in China[J]. Clin Mol Hepatol, 2024,30(2):135-143. [5] Jeng W J, Yip T C, Lok A S. Hepatitis B: a review. JAMA, 2026,335(21):1879-1892. [6] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华肝脏病杂志, 2022, 30(12):1309-1331. [7] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol,2025,83(2):502-583. [8] Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B Endorsed by the East Asia Liver Alliance (EALA)[J]. Clin Mol Hepatol,2026,32(3):1029-1116. [9] Lin C L, Kao J H. Global strategies and actions to eliminate hepatitis B virus infection[J]. Clin Mol Hepatol, 2025, 31(4):1197-1212. [10] World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection[R/OL]. (2024)[2026-8-31] https://www.ncbi.nlm.nik.gov/books/NBK614987/. [11] Garg H, Sarin S K, Kumar M, et al. Tenofovir improves the outcome in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure[J]. Hepatology, 2011, 53(3):774-780. [12] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2024年版)[J].中华肝脏病杂志,2025,33(1):18-33. [13] 中国医师协会感染科医师分会,国家感染性疾病临床医学研究中心.乙型肝炎全人群管理专家共识(2023)[J].中华临床感染病杂志,2024,17(1):1-13. [14] Tamaki N, Huang D Q, Lee H W, et al. Head-to-head comparison of long-term HCC risk of antivirals-treated versus untreated low-level viremia in HBV-compensated cirrhosis[J]. J Gastroenterol Hepatol,2025,40(6):1595-1601. [15] Lin W C, Lin K, Li M K, et al. Low level of hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in compensated cirrhotic patients[J]. World J Hepatol,2024,16(11):1321-1330. [16] Dusheiko G, Agarwal K, Maini M K,et al. New approaches to chronic hepatitis B[J]. N Engl J Med,2023,388(1):55-69. [17] Hong X, Cai Z, Zhou F, et al. Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models[J]. Front Pharmacol,2022,13:932934. [18] 程能能. 我国首个原研口服抗HBV药物TMF结构优势解读--神奇的甲基化[J].肝脏,2021,26(12):1303-1305. [19] You H, Wang F, Li T, et al. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022)[J]. J Clin Transl Hepatol. 2023;11(6):1425-1442. [20] 陈姝延, 孙亚朦, 王冰琼, 等. 慢性乙型肝炎低病毒血症诊疗管理进展[J]. 中华肝脏病杂志, 2022, 30(2):181-185. |